Protokinetix forges joint venture on anti-flammation skin care technology
Upon completion of the project to fully develop the formulation, the two companies will jointly offer it as a topical solution targeting skin inflammation for both cosmetic and pharmaceutical product lines.
The joint venture targets the fact that anti-inflammatory skin care products are used to treat conditions such as psoriasis, eczema and dermatitis with formulations that incorporate applications such as corticosteroids or immune modulators.
Avoiding long-term health risks
However, there are a number of associated long-term health risks with formulations that incorporate these type of applications, triggering the search for alternative solutions.
The formulation will incorporate Protokinetix’s AAGP technology, which the company says has been shown to demonstrate powerful anti-inflammation properties without any signs of potentially dangerous toxicity.
The companies say that the joint venture will result in a safer and effective alternative for both prescription and over-the-counter treatments for these increasingly common skin complaints.
Tapping into a market need
"There is a great need for new topical anti-inflammatory treatments to treat a wide variety of skin conditions, such as atopic dermatitis, eczema, and psoriasis," said Naomi Vishnupad, president and COO of Imaginative Research.
“Many of the available treatments have some undesirable side effects, and new therapeutic treatments would be considered an advancement in dermatology”, Vishnupad added.
Imaginative Research has partnered with several companies to platform the development and promotion of skin care formulations that have been used in products for both the cosmetics and pharmaceutical market.
